# Handoff: Feline Diabetes Model Endpoints (Branch Task)

**Date:** 2026-06-23
**Context:** This task was executed as a conscious "branch" from the main development line of Feline Research OS. The objective was to process a batch of reference materials (deep extractions of scientific literature) into "Gold Standard" Research Workspace outputs without interfering with the primary system architecture or main tasks.

## 1. Branch Objectives
- Safely ingest 6 raw "deep extract" markdown files provided by the user on the Desktop.
- Apply the strict "Research Workspace" codification standard: Evidence-based, rich in judgment, clear translation/recommendation value, and ZERO fabricated data.
- Ensure strict exclusion of unrelated topics (e.g., NewPets).
- Generate a comprehensive, multi-dimensional evaluation matrix for **Feline Diabetes Model Endpoints**.

## 2. Materials Processed
The following **7 Feline Diabetes papers** were processed (Batch 1 Complete):
1. *The Cat as a Model for Human Obesity and Diabetes* (Hoenig 2012)
2. *Insulin sensitivity in normal and diabetic cats* (Feldhahn 1999)
3. *Point-of-care β-hydroxybutyrate measurement for the diagnosis of feline diabetic ketoacidaemia* (Zeugswetter 2012)
4. *Routine kidney variables, glomerular filtration rate and urinary cystatin C in cats with diabetes mellitus, cats with chronic kidney disease and healthy cats* (Paepe 2015)
5. *Evaluation of routine hematology profile results and fructosamine, thyroxine, insulin, and proinsulin concentrations in lean, overweight, obese, and diabetic cats* (Hoenig 2013)
6. *Clinical usefulness of fructosamine measurements in diagnosing and monitoring feline diabetes mellitus* (Thoresen 1996)
7. *Feline Models of Type 2 Diabetes Mellitus* (Henson & O'Brien 2006) — **Added: IAPP/islet amyloidosis, Burmese cat genetics, chronic complications**

## 3. Pipeline Executed & Files Generated
The standard Feline Research OS knowledge extraction pipeline was followed:
**`Raw References -> Paper Cards -> Evidence Map -> Theme Synthesis -> Research Workspace Gold Matrix`**

All outputs have been safely isolated in the following directory:
`outputs/gold_standards/diabetes_model_endpoints/`

**Generated Assets:**
- **Paper Cards (7 files):** Located in `outputs/gold_standards/diabetes_model_endpoints/paper_cards/`. Each card contains standardized sections: paper positioning, research questions, core findings, methodology value, limitations, and translational inspiration.
- **Evidence Map (`evidence_map.md`):** A synthesis document mapping the 6 papers into distinct mechanistic themes (Pathological mechanisms, Early screening limitations, Short-term glycemic monitoring, Acute metabolic decompensation, and Kidney complications).
- **Research Workspace Gold Matrix (`research_workspace_gold.md`):** The final deliverable. A structured evaluation matrix classifying evaluation endpoints by dimension (Diagnosis/Enrollment, Short/Long-term Efficacy, Mechanism/Target Efficacy, Safety/Ketosis, Safety/Kidney, Stratification/Confounders), explicitly stating application scenarios and evidentiary boundaries.

## 4. Quality Assurance & Re-verification (100% Evidentiary Fidelity)
At the user's explicit request, a thorough re-read ("reread thorough") of all 7 source deep extracts was conducted against the generated Gold Standards. The following critical nuances and boundaries were successfully preserved:
- **Non-linear progression:** Fructosamine/glucose cannot reliably predict which obese cat will decompensate due to strong compensatory hyperinsulinemia.
- **Methodological Blind Spots:** The standard *insulin-modified FSIVGTT (MINMOD)* measures peripheral (skeletal muscle) resistance; it cannot quantify hepatic insulin resistance or hepatic glucose output.
- **Divergence from Human DKD:** Cats do not perfectly replicate human diabetic kidney disease. GFR changes are inconsistent, spontaneous atherosclerosis is absent, and significant proteinuria (UPC > 0.4) requires further longitudinal tracking (e.g., via UAC).
- **Masked Ketoacidosis:** POC β-HB > 2.55 mmol/L is highly sensitive for excluding DKA but lacks high specificity. Importantly, severe ketosis can be masked by a normal pH due to superimposed hypochloremic metabolic alkalosis.
- **Fructosamine Boundaries:** Excellent for distinguishing stress hyperglycemia and monitoring medium-term trends, but blind to brief hypoglycemic events and inadequate for micro-adjusting insulin doses.
- **IAPP/Islet Amyloidosis (Henson 2006):** Cats and humans share IAPP 20-29 region β-sheet propensity; rodents do not. This makes feline diabetes uniquely valuable for studying IAPP aggregation and β-cell apoptosis. Rodent models cannot replicate this without transgenic modification.
- **Burmese Cat Genetics:** ~4x higher diabetes prevalence (1/50 vs 1/200), suggesting complex genetic susceptibility. Valuable for genetic linkage studies.
- **Chronic Complications:** Cats can develop diabetic neuropathy (Schwann cell damage) and retinopathy (9-year follow-up shows microaneurysms, hemorrhages). Not suitable for atherosclerosis or hypertension endpoints.

## 5. Status & Next Steps
- **Status:** The branch task is **COMPLETE**. The Feline Diabetes Model Endpoints knowledge base is established, structured, and verified.
- **Next Steps:** 
  - Await the second batch of materials for the next branch task (e.g., insulin types, dietary management, SGLT2 inhibitors).
  - Or, resume work on the main Feline Research OS tasks, having safely isolated this knowledge extraction without disruption.
